Immunome annual current ratio
2019
2020
2021
2022
2023
2024
2025
Immunome Current Ratio Growth & History (IMNM)
Immunome's current ratio was 14.69 for fiscal 2025.
View full Immunome company overviewImmunome annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 14.69 | 10.61 | +260.36% |
| 2024 | 2024-12-31 | 4.08 | −2.55 | −38.52% |
| 2023 | 2023-12-31 | 6.63 | 3.54 | +114.56% |
| 2022 | 2022-12-31 | 3.09 | −2.73 | −46.94% |
| 2021 | 2021-12-31 | 5.82 | −8.30 | −58.76% |
| 2020 | 2020-12-31 | 14.12 | 12.24 | +652.99% |
| 2019 | 2019-12-31 | 1.88 | — | — |
Immunome quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 15.08 | 2.95 | +24.33% |
| Q1 2026 | 2026-03-31 | 21.68 | 11.19 | +106.63% |
| Q4 2025 | 2025-12-31 | 14.69 | 10.61 | +260.36% |
| Q3 2025 | 2025-09-30 | 8.90 | 2.73 | +44.19% |
| Q2 2025 | 2025-06-30 | 12.13 | 5.00 | +70.20% |
| Q1 2025 | 2025-03-31 | 10.49 | 0.31 | +3.03% |
| Q4 2024 | 2024-12-31 | 4.08 | −2.55 | −38.52% |
| Q3 2024 | 2024-09-30 | 6.17 | 2.22 | +56.09% |
| Q2 2024 | 2024-06-30 | 7.12 | 5.63 | +375.74% |
| Q1 2024 | 2024-03-31 | 10.18 | 8.31 | +443.38% |
| Q4 2023 | 2023-12-31 | 6.63 | 3.54 | +114.56% |
| Q3 2023 | 2023-09-30 | 3.96 | −0.01 | −0.31% |
| Q2 2023 | 2023-06-30 | 1.50 | −2.87 | −65.67% |
| Q1 2023 | 2023-03-31 | 1.87 | −2.90 | −60.71% |
| Q4 2022 | 2022-12-31 | 3.09 | −2.73 | −46.94% |
| Q3 2022 | 2022-09-30 | 3.97 | −3.91 | −49.65% |
| Q2 2022 | 2022-06-30 | 4.36 | −13.48 | −75.55% |
| Q1 2022 | 2022-03-31 | 4.77 | −4.22 | −46.96% |
| Q4 2021 | 2021-12-31 | 5.82 | −8.30 | −58.76% |
| Q3 2021 | 2021-09-30 | 7.88 | 6.50 | +469.30% |
| Q2 2021 | 2021-06-30 | 17.84 | — | — |
| Q1 2021 | 2021-03-31 | 8.99 | — | — |
| Q4 2020 | 2020-12-31 | 14.12 | 12.24 | +652.99% |
| Q3 2020 | 2020-09-30 | 1.38 | — | — |
| Q4 2019 | 2019-12-31 | 1.88 | — | — |
Immunome current ratio trends
Over the last five fiscal years, Immunome's current ratio increased from 14.12 to 14.69, a change of 0.57. The latest reported quarter, Q2 2026, shows 15.08.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗